Adam Chatoff

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Topics

Oxide Nanoparticles

Basal Cell Carcinoma

Acute Lymphoblastic Leukemia

Top Venues

Cancer research communications

Research square

This page only lists publications with an associated author ORCID identifier.

Publications

Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression. Cancer research communications (2024)
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression. Cancer research communications 4 (5) (2024)
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression. Cancer research communications 4 (5) (2024)
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression. Cancer research communications 4 (5) (2024)
Bakir Valentić, Andre Kelly, Alexander A Shestov, Zhiyang Gan, Feng Shen, Adam Chatoff, Alison Jaccard, Claudia V Crispim, John Scholler, Simon Heeke, Nathaniel W Snyder, Saba Ghassemi, Nicholas Jones, Saar I Gill, Roderick O'Connor
The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability. Research square (2024)
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression. Cancer research communications (2024)
Roderick O'Connor, Bakir Valentić, Andre Kelly, Alexander Shestov, Zhiyang Gan, Feng Shen, Adam Chatoff, Alison Jaccard, Claudia Crispim, John Scholler, Simon Heeke, Nathaniel W Snyder, Saba Ghassemi, Nicholas Jones, Saar I Gill
The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability. Research square (2024)
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression. Cancer research communications 4 (5) (2024)
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R Cole, Apoorva Uboveja, Richard Fang, Amandine Amalric, Baixue Yang, Adam Chatoff, Claudia V Crispim, Peter Sajjakulnukit, Maureen A Lyons, Kristine L Cooper, Nadine Hempel, Costas Andreas Lyssiotis, Uma R Chandran, Nathaniel W Snyder, Katherine Marie Aird
De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression. Cancer research communications (2024)